Know the Latest About COVID-19 Monoclonal Antibodies

Rising cases will renew focus on COVID-19 monoclonal antibodies (casirivimab/imdevimab, etc) for treating mild to moderate illness.

Patients. Expect your hospital to follow emergency use authorization (EUA) criteria for COVID-19 "mabs" in most cases.

This means usually dispensing them for COVID-19 OUTpatients age 12 or older...with mild to moderate symptoms for less than 10 days...and at high risk of severe COVID-19 (diabetes, etc).

Get unlimited access through an Enterprise license

Hospital Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals